Open Scanner

Specify a stock or a cryptocurrency in the search bar to get a summary

Internet Computer ICP
Bitcoin Cash BCH
Litecoin LTC
Field stub for analysis

Bristol-Myers Squibb Company

BMYMP
Current price
870 USD 0 USD (0.00%)
Last closed 50.92 USD
Sector Healthcare
Industry Drug Manufacturers - General
Exchange NYSE
Capitalization 102 909 247 488 USD
Yield for 12 month -26.57 %
1Y
3Y
5Y
10Y
15Y
BMYMP
21.11.2021 - 28.11.2021

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, and neuroscience diseases. The company's products include Eliquis for reduction in risk of stroke/systemic embolism in non-valvular atrial fibrillation, and for the treatment of DVT/PE; Opdivo for various anti-cancer indications, including bladder, blood, CRC, head and neck, RCC, HCC, lung, melanoma, MPM, stomach and esophageal cancer; Pomalyst/Imnovid for multiple myeloma; Orencia for active rheumatoid arthritis and psoriatic arthritis; and Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia. It also provides Yervoy for the treatment of patients with unresectable or metastatic melanoma; Empliciti for the treatment of multiple myeloma; Abecma for the treatment of relapsed or refractory multiple myeloma; Reblozyl for the treatment of anemia; Opdualag for the treatment of unresectable or metastatic melanoma; and Zeposia to treat relapsing forms of multiple sclerosis. In addition, the company offers Breyanzi for the treatment of relapsed or refractory large B-cell lymphoma; Onureg for the treatment of AML; Inrebic for the treatment of myelofibrosis; Camzyos for the treatment of symptomatic obstructive HCM to enhance functional capacity and symptom; Sotyktu for the treatment of moderate-to-severe plaque psoriasis; Augtyro for the treatment of locally advanced or metastatic ROS1-positive NSCLC; Revlimid, an oral immunomodulatory drug for the treatment of multiple myeloma; and Abraxane to treat breast cancer, NSCLC and pancreatic cancer. It sells products to wholesalers, distributors, pharmacies, retailers, hospitals, clinics, and government agencies. The company was formerly known as Bristol-Myers Company. Bristol-Myers Squibb Company was founded in 1887 and is headquartered in Princeton, New York. Address: Route 206 & Province Line Road, Princeton, NY, United States, 08543

Check your investment idea

Find the best to beat the market
TSLA TSLA Tesla Motors
AAPL AAPL Apple
MSFT MSFT Microsoft

Analytics

WallStreet Target Price

56.3 USD

P/E ratio

13.1839

Dividend Yield

4.73 %

Current Year

+45 006 000 000 USD

Last Year

+46 159 000 000 USD

Current Quarter

+11 477 000 000 USD

Last Quarter

+10 966 000 000 USD

Current Year

+34 313 000 000 USD

Last Year

+36 022 000 000 USD

Current Quarter

+8 732 000 000 USD

Last Quarter

+8 460 000 000 USD

Key Figures BMYMP

1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
EBITDA 18 420 000 768 USD
Operating Margin TTM 17.01 %
PE Ratio 13.1839
Return On Assets TTM 5.63 %
PEG Ratio 2.3003
Return On Equity TTM 26.53 %
Wall Street Target Price 56.3 USD
Revenue TTM 45 006 000 128 USD
Book Value 14.56 USD
Revenue Per Share TTM 21.75 USD
Dividend Share 2.31 USD
Quarterly Revenue Growth YOY 0.6 %
Dividend Yield 4.73 %
Gross Profit TTM 36 378 000 000 USD
Earnings Share 3.86 USD
Diluted Eps TTM 3.86 USD
Most Recent Quarter IV 2023
Quarterly Earnings Growth YOY -8.9 %
Profit Margin 17.83 %

Dividend Analytics BMYMP

Dividend growth over 5 years

78 %

Continuous growth

2 years

Payout Ratio 5 years average

87 %

Dividend History BMYMP

1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
Forward Annual Dividend Rate 2.4
Ex Dividend Date 04.01.2024
Forward Annual Dividend Yield 4.73 %
Last Split Factor 1000000:95
Payout Ratio 30.8 %
Last Split Date 07.08.2001
Dividend Date 01.02.2024

Stock Valuation BMYMP

1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
Trailing PE 13.1839
Forward PE 7.1327
Enterprise Value Revenue 2.9287
Price Sales TTM 2.2866
Enterprise Value EBITDA 6.8063
Price Book MRQ 3.4871

Financials BMYMP

1 year
3 years
5 years
10 years
15 years
Results 2019 Dynamics
* The data for this period has not yet been published

Technical indicators BMYMP

For 52 weeks

47.58 USD 68.94 USD
50 Day MA 50.38 USD
Shares Short Prior Month 29 186 038
200 Day MA 56.88 USD
Short Ratio 1.96
Shares Short 31 494 336
Short Percent 1.56 %

Dynamics of changes in the value of assets

Stocks


MSFT

MSFT

415.39 USD Microsoft Corporation +1.75 (+0.42%)
Detailed analytics

ETF funds


M

MDAXEX

206.85 CHF iShares MDAX UCITS ETF (DE) +1.13 (+0.49%)
Detailed analytics

Metals


Gold

2083 USD Gold -0.06 (-0%)
Detailed analytics